DOCSLIB.ORG

Primary Immunodeficiency Patient Information

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Primary Immunodeficiency Patient Information Primary Immunodeficiencies Patient Information Instructions: The accurate interpretation and reporting of genetic results is contingent upon the reason for referral, clinical information, ethnic background, and family history. To help provide the best possible service, supply the information requested below and send paperwork with the specimen, or return by fax to Mayo Clinic Laboratories, Attn: Personalized Genomics Laboratory Genetic Counselors at 507-284-1759. Phone: 507-266-5700 / International clients: +1-507-266-5700 or email [email protected] Patient Information Patient Name (Last, First, Middle) Birth Date (mm-dd-yyyy) Sex Male Female Referring Provider Name (Last, First) Phone Fax* Other Contact Name (Last, First) Phone Fax* *Fax number given must be from a fax machine that complies with applicable HIPAA regulations. Reason for Testing Diagnosis Newborn Screening Follow-up Carrier Testing Family History Note: Genetic testing should always be initiated on an affected family member first, when available, in order to be most informative for at-risk relatives. Indications Check all that apply. Autoinflammatory Inflammatory Bowel Disease/ Severe Combined Immunodeficiency Periodic fever Enteropathy/Hepatic PID Severe combined immunodeficiency (SCID) Familial Mediterranean fever (FMF) Chronic IBD-like disorder and CID Combined immunodeficiency (CID) Hyper IgD syndrome Ulcerative colitis T-cell lymphopenia/deficiency Cryopyrin-associated periodic Crohn disease (T-, B-, NK-) SCID (ADA-SCID; syndromes (CAPS) Enteropathy, hypogammaglobulinemia, Reticular dysgenesis) Blau syndrome autoinflammation, and autoimmunity (T-, B-, NK+) SCID PAPA syndrome IBD, lymphadenopathy (VDJ recombination defects; CID) PFAPA syndrome Veno-occlusive disease (T-, B+, NK-) SCID TRAPS (TNF-receptor-associated (in context of PID; VODI) (X-linked SCID; JAK3 SCID) periodic syndromes) NRH (nodular regenerative (T-, B+, NK+) SCID (T-cell SCID) PLAID/APLAID hyperplasia) Severe, recurrent EBV infections/ Amylopectinosis and autoinflammation ENB lymphoproliferative disease Majeed syndrome; CRMO Phagocytic PID/ CD4+ or CD8+ T-cell deficiency or absence Other inflammasome-related disorders Chronic Granulomatous Disease of MHC class I or class II molecules Other autoinflammatory conditions, Recurrent pneumonia, soft-tissue (Bare lymphocyte syndrome, type I or II) granulomas, recurrent abscesses, specify: _____________________ specific microbial infections; specify: Telomere Defects B-Cell Deficiency; Agammaglobulinemia ____________________________ Idiopathic pulmonary fibrosis Recurrent sinopulmonary infections Palmoplantar keratoderma with Dyskeratosis congenita Hypogammaglobulinemia periodontitis (Papillon-Lefvre) Bone marrow failure syndrome Lymphoproliferation Delayed umbilical cord separation +/- Telomeropathies omphalitis Increased IgM (Hyper IgM) Leukocytosis Congenital Neutropenia/Neutrophil PID Class-switch recombination defects Absence of pus (leukocyte adhesion Congenital neutropenia (Kostmann deficiencies) syndrome) Complement aHUS/TMA Atypical hemolytic uremic syndrome Bleeding diathesis Cyclic neutropenia (aHUS) Comel-Netherton syndrome Shwachman-Diamond syndrome Thrombotic microangiopathy (TMA) Favism (hemolysis, neonatal Wiskott-Aldrich syndrome Thrombotic thrombocytopenic purpura hyperbilirubinemia) Cohen syndrome (TTP) Pulmonary alveolar proteinosis Barth syndrome Other neutrophil-associated G6PD deficiency phenotypes WHIM syndrome Bombay blood group Other neutropenia, specify: Gingivitis ________________________________ Periodontitis T791 ©2021 Mayo Foundation for Medical Education and Research Page 1 of 3 MC1235-248rev0221 Primary Immunodeficiencies Patient Information (continued) Patient Name (Last, First, Middle) Birth Date (mm-dd-yyyy) Family History Attach Pedigree if available. Are there any affected relatives? Yes No If yes, relationship: ___________________________________________________________________________________________ Is there any consanguinity in the family? Yes No Have relatives had molecular genetic testing? Yes No If yes, specify: ______________________________________________________________________________________________ Ethnicity European Caucasian African American Hispanic Asian Other: ___________________________________________ Clinical History Check all that apply. Age of onset of symptoms: ________ Durations of symptoms: ____________________________________________________________ Has the patient received a hematopoietic cell transplant? Yes No If yes, transplant date (mm-dd-yyyy): _______________________ Transplant type: allogeneic (MRD, MURD, haplo, cord, BM): _____________________________________________________________ Donor chimerism: % T: __________ % B: __________ % NK: __________ % myeloid: __________ Has the patient received a solid organ transplant? Yes No If yes, Heart Lung Liver Kidney Vascularized Composite allograph Other, specify: ____________________________________________________________________________________________ First transplant or multiple: _____________________________________________________________________________________ Post-transplant immunosuppression Graft versus host disease? Yes: Acute Chronic No Laboratory Findings Cytokines Complement Serology Abnormal lymphocyte (T-, B-, IL-1b: Increased Decreased CH50: Normal Abnormal and NK-cell) subset quantitation: IL-6: Increased Decreased AH50: Normal Abnormal ____________________________ IL-18: Increased Decreased FH autoantibody: Yes No TNF alpha: Increased Decreased FH: Normal Abnormal Humoral Markers Interferon-gamma: FB: Normal Abnormal Abnormal B-cell function Increased Decreased (vaccine antibody responses): FI: Normal Abnormal Chromosomal Studies ____________________________ FD: Normal Abnormal 22q deletion FISH Autoantibodies present, specify: sMAC: Normal Abnormal Chromosomal array ____________________________ aHUS serology panel Other chromosomal abnormality Hypogammaglobulinemia: C2 level: ____________ _____________________________ IgG IgA IgM Function: Normal Abnormal IgD IgE Protein Loss Markers C3 level: ____________ Hypergammaglobulinemia: Calprotectin Function: Normal Abnormal IgG IgA IgM 24-hour stool alpha-1 antitrypsin C4 level: ____________ IgD IgE clearance assay Function: Normal Abnormal Serum albumin C5 level: ____________ Cellular Markers Proteinuria: Yes No Function: Normal Abnormal Abnormal TREC assay (NBS and/or C6–C9 level: _________ other): ______________________ Soluble Biomarkers Function: Normal Abnormal Abnormal T-cell function (specify ADAMTS13 C1q level: ___________ mitogens/antigens/anti-CD3/cytokine Activity: ________ Level: ________ Function: Normal Abnormal production); Shiga toxin: Positive Negative C1q antibody: Yes No T-cell markers: Vitamin B12: ___________________ C3NeF: Yes No Naive: Increased Decreased Folate: _______________________ Other: __________________________ Memory: Increased Decreased Ferritin: _______________________ Activated: Soluble IL2R-alpha (sCD25): _______ Other Markers Increased Decreased Abnormal radiosensitivity: Yes No B-cell markers: CRP: _________________________ (blood, MB, or fibroblasts) Switched memory: ESR: _________________________ Specific protein assay by flow cytometry: Increased Decreased Triglycerides: __________________ BTK: Normal Abnormal Marginal zone B-cells: Fibrinogen: ____________________ Increased Decreased LRBA: Normal Abnormal AFP level (age when tested): _______ DOCK8: Normal Abnormal Transitional B-cells: ALPS screening panel: Increased Decreased WAS: Normal Abnormal DNT-cell % as % CD3+ : __________ Plasmablasts: XIAP: Normal Abnormal Increased Decreased sFASL: Increased Abnormal SAP: Normal Abnormal Page 2 of 3 MC1235-248rev0221 Primary Immunodeficiencies Patient Information (continued) Patient Name (Last, First, Middle) Birth Date (mm-dd-yyyy) Other Markers (continued) Anti-granulocyte antibody Other Clinical Symptoms: Functional studies: COOMBS test: Positive Negative __________________________________ T-cell: Normal Abnormal Lymphangiectasia, location: __________________________________ (specify mitogens/antigens/anti-CD3/ ______________________________ cytokine production) __________________________________ STAT signaling: Oncologic History __________________________________ Normal Abnormal Myelodysplasia/AML DHR: Normal Abnormal Lymphoma, specify: Medications Calcium signaling: ______________________________ On immunosuppressant therapy? Normal Abnormal Solid tumor, specify: Yes No Other: __________________________ ______________________________ Previous immunosuppressant therapy: Telomere length: Leukemia, specify: Duration: ____________________ Lymphoid: Normal <10% <1% ______________________________ Date of use: __________________ Myeloid: Normal <10% <1% Recurrent primary tumors, specify: Other Comments: ADA1: ______________________________ Activity: ________ Level: ________ __________________________________ Other: _________________________ ADA2: __________________________________ Activity: ________ Level: ________ Head and Neck __________________________________ PNP: Dysmorphic facies, specify: __________________________________ Activity: ________ Level: ________ ______________________________ __________________________________ Other findings: ______________________ Lymphadenopathy __________________________________ _________________________________ Microcephaly Oral leukoplakia Infectious Disease History Small lymph nodes and/or tonsils Recurrent, difficult to treat infections: Thymic hypoplasia Attach clinical notes if
Load more

Recommended publications
  • IDF Patient & Family Handbook
    Immune Deficiency Foundation Patient & Family Handbook for Primary Immunodeficiency Diseases This book contains general medical information which cannot be applied safely to any individual case. Medical knowledge and practice can change rapidly. Therefore, this book should not be used as a substitute for professional medical advice. FIFTH EDITION COPYRIGHT 1987, 1993, 2001, 2007, 2013 IMMUNE DEFICIENCY FOUNDATION Copyright 2013 by Immune Deficiency Foundation, USA. REPRINT 2015 Readers may redistribute this article to other individuals for non-commercial use, provided that the text, html codes, and this notice remain intact and unaltered in any way. The Immune Deficiency Foundation Patient & Family Handbook may not be resold, reprinted or redistributed for compensation of any kind without prior written permission from the Immune Deficiency Foundation. If you have any questions about permission, please contact: Immune Deficiency Foundation, 110 West Road, Suite 300, Towson, MD 21204, USA; or by telephone at 800-296-4433. Immune Deficiency Foundation Patient & Family Handbook for Primary Immunodeficency Diseases 5th Edition This publication has been made possible through a generous grant from Baxalta Incorporated Immune Deficiency Foundation 110 West Road, Suite 300 Towson, MD 21204 800-296-4433 www.primaryimmune.org [email protected] EDITORS R. Michael Blaese, MD, Executive Editor Francisco A. Bonilla, MD, PhD Immune Deficiency Foundation Boston Children’s Hospital Towson, MD Boston, MA E. Richard Stiehm, MD M. Elizabeth Younger, CPNP, PhD University of California Los Angeles Johns Hopkins Los Angeles, CA Baltimore, MD CONTRIBUTORS Mark Ballow, MD Joseph Bellanti, MD R. Michael Blaese, MD William Blouin, MSN, ARNP, CPNP State University of New York Georgetown University Hospital Immune Deficiency Foundation Miami Children’s Hospital Buffalo, NY Washington, DC Towson, MD Miami, FL Francisco A.
    [Show full text]
  • Immunology in Pediatric Dentistry
    PEDIATRIC DENTISTRY/Copynght© 1983 by The American Academy of Pedodontics/Vol. 5, No. 3 Immunology in pediatric dentistry William C. Donlon, DMD, MA Abstract The scope of clinical immunology is ever- usually are directed against a specific allergen and this increasing. A working knowledge of the immune substance will always invoke the same type of response system and its disease states is important in the although the severity may vary. Another variable is evalution and treatment of pediatric dental patients. whether the reaction is localized or generalized. This review focuses both on immune conditions with The antibody type which initiates the histamine- a possible iatrogenic origin, such as allergy, and releasing immediate atopic reaction is IgE. Molecule immune phenomena which the pedodontist may dimers of IgE adhere to most cells and basophils causing diagnose or treat as part of the medical team. degranulation and subsequent increase in extracellular levels of vasodilators such as histamine, slow-reacting substance - A, and the kinins. Clinical symptoms are "ue to advances in the science of immunology, pa- cutaneous wheal and flare, edema, rhinorrhea, tearing, tients with defects of the immune system are being possible respiratory embarrassment, and hypotension diagnosed earlier and living longer. The condition and/or (Figure 1). treatment modality may affect the patient's oral health Antihistamines are the most effective treatment in mild and delivery of dental care. On a more mundane level, cases. Active therapy of allergy may include induction of the pedodontist deals with the immune system daily when IgG antibody synthesis by multiple injections of minute inquiring about allergies and rheumatic fever in the quantities of the allergen.
    [Show full text]
  • Our Immune System (Children's Book)
    OurOur ImmuneImmune SystemSystem A story for children with primary immunodeficiency diseases Written by IMMUNE DEFICIENCY Sara LeBien FOUNDATION A note from the author The purpose of this book is to help young children who are immune deficient to better understand their immune system. What is a “B-cell,” a “T-cell,” an “immunoglobulin” or “IgG”? They hear doctors use these words, but what do they mean? With cheerful illustrations, Our Immune System explains how a normal immune system works and what treatments may be necessary when the system is deficient. In this second edition, a description of a new treatment has been included. I hope this book will enable these children and their families to explore together the immune system, and that it will help alleviate any confusion or fears they may have. Sara LeBien This book contains general medical information which cannot be applied safely to any individual case. Medical knowledge and practice can change rapidly. Therefore, this book should not be used as a substitute for professional medical advice. SECOND EDITION COPYRIGHT 1990, 2007 IMMUNE DEFICIENCY FOUNDATION Copyright 2007 by Immune Deficiency Foundation, USA. Readers may redistribute this article to other individuals for non-commercial use, provided that the text, html codes, and this notice remain intact and unaltered in any way. Our Immune System may not be resold, reprinted or redistributed for compensation of any kind without prior written permission from Immune Deficiency Foundation. If you have any questions about permission, please contact: Immune Deficiency Foundation, 40 West Chesapeake Avenue, Suite 308, Towson, MD 21204, USA; or by telephone at 1-800-296-4433.
    [Show full text]
  • Ataxia..Telangiectasia and Cellular Responses to DNA Damage'
    (CANCERRESEARCH55. 5991-6001. December 15, 19951 Review Ataxia..Telangiectasia and Cellular Responses to DNA Damage' M. Stephen Meyn2 Departments of Genetics and Pediatrics, Yale University School of Medicine, New Haven, connecticut 06510 Abstract elevated frequencies of spontaneous and induced chromosome aber rations, high spontaneous rates of intrachromosomal recombination, Ataxia-telangiectasia (A-T) is a human disease characterized by high aberrant immune gene rearrangements, and inability to arrest the cell cancer risk, immune defects, radiation sensitivity, and genetic instability. Although A-T homozygotes are rare, the A-T gene may play a role in cycle in response to DNA damage (3—6)]. sporadic breast cancer and other common cancers. Abnormalities of DNA The nature of the A-T defect has been the subject of much repair, genetic recombination, chromatin structure, and cell cycle check speculation; most hypotheses focus on the radiation sensitivity of point control have been proposed as the underlying defect in A-T; how A-T cells. Early reports that A-T fibroblasts were unable to excise ever, previous models cannot satisfactorily explain the plelotropic A-T radiation-induced DNA adducts prompted suggestions that the phenotype. radiation sensitivity of A-T cells was due to an intrinsic defect in Two recent observations help clarify the molecular pathology of A-T: DNA repair (7). However, subsequent work indicated that not all (a) inappropriate p53-mediated apoptosis is the major cause of death in A-T fibroblasts have a defect in DNA adduct excision (8), and that A-T cells irradiated in culture; and (b) ATM, the putative gene for A-T, has extensive homology to several celi cycle checkpoint genes from other the kinetics of repair of DNA breaks and chromosome aberrations organisms.
    [Show full text]
  • IDF Guide to Hematopoietic Stem Cell Transplantation
    Guide to Hematopoietic Stem Cell Transplantation Immune Deficiency Foundation Guide to Hematopoietic Stem Cell Transplantation This publication contains general medical information that cannot be applied safely to any individual case. Medical knowledge and practice can change rapidly. Therefore, this publication should not be used as a substitute for professional medical advice. In all cases, patients and caregivers should consult their healthcare providers. Each patient’s condition and treatment are unique. Copyright 2018 by Immune Deficiency Foundation, USA Readers may redistribute this guide to other individuals for non-commercial use, provided that the text, html codes, and this notice remain intact and unaltered in any way. Immune Deficiency Foundation Guide to Hematopoietic Stem Cell Transplantation may not be resold, reprinted or redistributed for compensation of any kind without prior written permission from the Immune Deficiency Foundation (IDF). If you have any questions about permission, please contact: Immune Deficiency Foundation, 110 West Road, Suite 300, Towson, MD 21204, USA, or by telephone: 800-296-4433. For more information about IDF, go to: www.primaryimmune.org. This publication has been made possible through the IDF SCID Initiative and the SCID, Angels for Life Foundation. Acknowledgements The Immune Deficiency Foundation would like to thank the organizations and individuals who helped make this publication possible and contributed to the development of the Immune Deficiency Foundation Guide to Hematopoietic Stem
    [Show full text]
  • Theory of an Immune System Retrovirus
    Proc. Nati. Acad. Sci. USA Vol. 83, pp. 9159-9163, December 1986 Medical Sciences Theory of an immune system retrovirus (human immunodeficiency virus/acquired immune deficiency syndrome) LEON N COOPER Physics Department and Center for Neural Science, Brown University, Providence, RI 02912 Contributed by Leon N Cooper, July 23, 1986 ABSTRACT Human immunodeficiency virus (HIV; for- initiates clonal expansion, sustained by interleukin 2 and y merly known as human T-cell lymphotropic virus type interferon. Ill/lymphadenopathy-associated virus, HTLV-Ill/LAV), the I first give a brief sketch of these events in a linked- retrovirus that infects T4-positive (helper) T cells of the interaction model in which it is assumed that antigen-specific immune system, has been implicated as the agent responsible T cells must interact with the B-cell-processed virus to for the acquired immune deficiency syndrome. In this paper, initiate clonal expansion (2). I then assume that virus-specific I contrast the growth of a "normal" virus with what I call an antibody is the major component ofimmune system response immune system retrovirus: a retrovirus that attacks the T4- that limits virus spread. As will be seen, the details of these positive T cells of the immune system. I show that remarkable assumptions do not affect the qualitative features of my interactions with other infections as well as strong virus conclusions. concentration dependence are general properties of immune Linked-Interaction Model for Clonal Expansion of Lympho- system retroviruses. Some of the consequences of these ideas cytes. Let X be the concentration of normal infecting virus are compared with observations.
    [Show full text]
  • Cells, Tissues and Organs of the Immune System
    Immune Cells and Organs Bonnie Hylander, Ph.D. Aug 29, 2014 Dept of Immunology [email protected] Immune system Purpose/function? • First line of defense= epithelial integrity= skin, mucosal surfaces • Defense against pathogens – Inside cells= kill the infected cell (Viruses) – Systemic= kill- Bacteria, Fungi, Parasites • Two phases of response – Handle the acute infection, keep it from spreading – Prevent future infections We didn’t know…. • What triggers innate immunity- • What mediates communication between innate and adaptive immunity- Bruce A. Beutler Jules A. Hoffmann Ralph M. Steinman Jules A. Hoffmann Bruce A. Beutler Ralph M. Steinman 1996 (fruit flies) 1998 (mice) 1973 Discovered receptor proteins that can Discovered dendritic recognize bacteria and other microorganisms cells “the conductors of as they enter the body, and activate the first the immune system”. line of defense in the immune system, known DC’s activate T-cells as innate immunity. The Immune System “Although the lymphoid system consists of various separate tissues and organs, it functions as a single entity. This is mainly because its principal cellular constituents, lymphocytes, are intrinsically mobile and continuously recirculate in large number between the blood and the lymph by way of the secondary lymphoid tissues… where antigens and antigen-presenting cells are selectively localized.” -Masayuki, Nat Rev Immuno. May 2004 Not all who wander are lost….. Tolkien Lord of the Rings …..some are searching Overview of the Immune System Immune System • Cells – Innate response- several cell types – Adaptive (specific) response- lymphocytes • Organs – Primary where lymphocytes develop/mature – Secondary where mature lymphocytes and antigen presenting cells interact to initiate a specific immune response • Circulatory system- blood • Lymphatic system- lymph Cells= Leukocytes= white blood cells Plasma- with anticoagulant Granulocytes Serum- after coagulation 1.
    [Show full text]
  • Agammaglobulinemia Hypogammaglobulinemia Hereditary Disease Immunoglobulins
    Pediat. Res. 2: 72-84 (1968) Agammaglobulinemia hypogammaglobulinemia hereditary disease immunoglobulins Hereditary Alterations in the Immune Response: Coexistence of 'Agammaglobulinemia', Acquired Hypogammaglobulinemia and Selective Immunoglobulin Deficiency in a Sibship REBECCA H. BUCKLEY[75] and J. B. SIDBURY, Jr. Departments of Pediatrics, Microbiology and Immunology, Division of Immunology, Duke University School of Medicine, Durham, North Carolina, USA Extract A longitudinal immunologic study was conducted in a family in which an entire sibship of three males was unduly susceptible to infection. The oldest boy's history of repeated severe infections be- ginning in infancy and his marked deficiencies of all three major immunoglobulins were compatible with a clinical diagnosis of congenital 'agammaglobulinemia' (table I, fig. 1). Recurrent severe in- fections in the second boy did not begin until late childhood, and his serum abnormality involved deficiencies of only two of the major immunoglobulin fractions, IgG and IgM (table I, fig. 1). This phenotype of selective immunoglobulin deficiency is previously unreported. Serum concentrations of the three immunoglobulins in the youngest boy (who also had a late onset of repeated infection) were normal or elevated when he was first studied, but a marked decline in levels of each of these fractions was observed over a four-year period (table I, fig. 1). We could find no previous reports describing apparent congenital and acquired immunologic deficiencies in a sibship. Repeated infections and demonstrated specific immunologic unresponsiveness preceded gross ab- normalities in the total and fractional gamma globulin levels in both of the younger boys (tables II-IV). When the total immunoglobulin level in the second boy was 735 mg/100 ml, he failed to respond with a normal rise in titer after immunization with 'A' and 'B' blood group substances, diphtheria, tetanus, or Types I and II poliovaccines.
    [Show full text]
  • Chapter 2 Agammaglobulinemia: X-Linked and Autosomal Recessive
    Agammaglobulinemia: X-Linked and Autosomal Recessive Chapter 2 Agammaglobulinemia: X-Linked and Autosomal Recessive The basic defect in both X-Linked Agammaglobulinemia and autosomal recessive agammaglobulinemia is a failure of B-lymphocyte precursors to mature into B-lymphocytes and ultimately plasma cells. Since they lack the cells that are responsible for producing immunoglobulins, these patients have severe deficiencies of all types of immunoglobulins. Definition of X-Linked Agammaglobulinemia (XLA) and Autosomal Recessive Agammaglobulinemia (ARA) X-Linked Agammaglobulinemia (XLA) was first are not coated with antibody. All of these actions described in 1952 by Dr. Ogden Bruton. This disease, prevent germs from invading body tissues where they sometimes called Bruton’s Agammaglobulinemia or may cause serious infections. (See chapter titled “The Congenital Agammaglobulinemia, was one of the first Immune System and Primary Immunodeficiency immunodeficiency diseases to be identified. XLA is an Diseases.”) inherited immunodeficiency disease in which patients The basic defect in XLA is an inability of the patient to lack the ability to produce antibodies, the proteins that produce antibodies. Antibodies are produced by make up the gamma globulin or immunoglobulin specialized cells in the body, called plasma cells. fraction of blood plasma. Plasma cells develop in an orderly sequence of steps Antibodies are an integral part of the body’s defense beginning with stem cells located in the bone marrow. mechanism against certain types of microorganisms or The stem cells give rise to immature lymphocytes, germs, like bacteria or viruses. Antibodies are important called pro-B-lymphocytes. Pro-B-lymphocytes next in the recovery from infections and protect against develop into pre-B-cells, which then give rise to getting certain infections more than once.
    [Show full text]
  • Ataxia Telangiectasia: a Diagnostic Challenge. Case Report
    case reports 2020; 6(2) https://doi.org/10.15446/cr.v6n2.83219 ATAXIA TELANGIECTASIA: A DIAGNOSTIC CHALLENGE. CASE REPORT Keywords: Ataxia Telangiectasia; Neurodegenerative Diseases; Cerebellar Ataxia; Spinocerebellar Degenerations; Telangiectasia. Palabras clave: Ataxia telangiectasia; Enfermedades neurodegenerativas; Ataxia cerebelosa; Degeneraciones espinocerebelosa; Telangiectasia. Natalia Martínez-Córdoba Universidad Militar Nueva Granada - Faculty of Medicine - Pediatric Neurology Research Group - Bogotá D.C. - Colombia. Hospital Militar Central - Pediatric Neurology Service - Bogotá D.C. - Colombia. Eugenia Espinosa-García Universidad Militar Nueva Granada - Faculty of Medicine - Pediatric Neurology Research Group - Bogotá D.C. - Colombia. Hospital Militar Central - Pediatric Neurology Service - Bogotá D.C. - Colombia. Universidad del Rosario - Medical School - Bogotá D.C. - Colombia. Corresponding author Natalia Martínez-Córdoba. Faculty of Medicine, Universidad Militar Nueva Granada. Bogotá D.C. Colombia. Email: [email protected]. Received: 28/10/2019 Accepted: 08/01/2020 case reports Vol. 6 No. 2: 109-17 110 RESUMEN ABSTRACT Introducción. La ataxia-telangiectasia (AT) es Introduction: Ataxia-telangiectasia (AT) is a un síndrome neurodegenerativo con baja inciden- neurodegenerative syndrome with low incidence cia y prevalencia mundial que es causado por una and prevalence worldwide, which is caused by a mutación del gen ATM, es de herencia autosó- mutation of the ATM gene. It is an autosomal re- mica recesiva y se asocia a mecanismos defec- cessive disorder that is associated with defective tuosos en la regeneración y reparación del ADN. cell regeneration and DNA repair mechanisms. It Este síndrome se caracteriza por la presencia de is characterized by progressive cerebellar atax- ataxia cerebelosa progresiva, movimientos ocula- ia, abnormal eye movements, oculocutaneous res anormales, telangiectasias oculocutáneas e telangiectasias and immunodeficiency.
    [Show full text]
  • Practice Parameter for the Diagnosis and Management of Primary Immunodeficiency
    Practice parameter Practice parameter for the diagnosis and management of primary immunodeficiency Francisco A. Bonilla, MD, PhD, David A. Khan, MD, Zuhair K. Ballas, MD, Javier Chinen, MD, PhD, Michael M. Frank, MD, Joyce T. Hsu, MD, Michael Keller, MD, Lisa J. Kobrynski, MD, Hirsh D. Komarow, MD, Bruce Mazer, MD, Robert P. Nelson, Jr, MD, Jordan S. Orange, MD, PhD, John M. Routes, MD, William T. Shearer, MD, PhD, Ricardo U. Sorensen, MD, James W. Verbsky, MD, PhD, David I. Bernstein, MD, Joann Blessing-Moore, MD, David Lang, MD, Richard A. Nicklas, MD, John Oppenheimer, MD, Jay M. Portnoy, MD, Christopher R. Randolph, MD, Diane Schuller, MD, Sheldon L. Spector, MD, Stephen Tilles, MD, Dana Wallace, MD Chief Editor: Francisco A. Bonilla, MD, PhD Co-Editor: David A. Khan, MD Members of the Joint Task Force on Practice Parameters: David I. Bernstein, MD, Joann Blessing-Moore, MD, David Khan, MD, David Lang, MD, Richard A. Nicklas, MD, John Oppenheimer, MD, Jay M. Portnoy, MD, Christopher R. Randolph, MD, Diane Schuller, MD, Sheldon L. Spector, MD, Stephen Tilles, MD, Dana Wallace, MD Primary Immunodeficiency Workgroup: Chairman: Francisco A. Bonilla, MD, PhD Members: Zuhair K. Ballas, MD, Javier Chinen, MD, PhD, Michael M. Frank, MD, Joyce T. Hsu, MD, Michael Keller, MD, Lisa J. Kobrynski, MD, Hirsh D. Komarow, MD, Bruce Mazer, MD, Robert P. Nelson, Jr, MD, Jordan S. Orange, MD, PhD, John M. Routes, MD, William T. Shearer, MD, PhD, Ricardo U. Sorensen, MD, James W. Verbsky, MD, PhD GlaxoSmithKline, Merck, and Aerocrine; has received payment for lectures from Genentech/ These parameters were developed by the Joint Task Force on Practice Parameters, representing Novartis, GlaxoSmithKline, and Merck; and has received research support from Genentech/ the American Academy of Allergy, Asthma & Immunology; the American College of Novartis and Merck.
    [Show full text]
  • Primary Immunodeficiency Disorders
    ALLERGY AND IMMUNOLOGY 00954543 /98 $8.00 + .OO PRIMARY IMMUNODEFICIENCY DISORDERS Robert J. Mamlok, MD Immunodeficiency is a common thought among both patients and physicians when confronted with what is perceived as an excessive num- ber, duration, or severity of infections. Because of this, the starting point for evaluating patients for suspected immunodeficiency is based on what constitutes ”too many infections.” It generally is agreed that children with normal immune systems may have an average of 6 to 8 respiratory tract infections per year for the first decade of life. Even after a pattern of ab- normal infection is established, questions of secondary immunodeficiency should first be raised. The relatively uncommon primary immunodefi- ciency diseases are statistically dwarfed by secondary causes of recurrent infection, such as malnutrition, respiratory allergy, chronic cardiovascular, pulmonary, and renal disease, and environmental factors. On the other hand, a dizzying spiral of progress in our understanding of the genetics and immunology of primary immunodeficiency disease has resulted in improved diagnostic and therapeutic tools. Twenty-five newly recognized immunologic disease genes have been cloned in the last 5 ~ears.2~It has become arguably more important than ever for us to recognize the clinical and laboratory features of these relatively uncommon, but increasingly treatable, disorders. CLASSIFICATION The immune system has been classically divided into four separate arms: The B-cell system responsible for antibody formation, the T-cell sys- From the Division of Pediatric Allergy and Immunology, Texas Tech University Health Sci- ences Center, Lubbock, Texas PRIMARY CARE VOLUME 25 NUMBER 4 DECEMBER 1998 739 740 MAMLOK tem responsible for immune cellular regulation, the phagocytic (poly- morphonuclear and mononuclear) system and the complement (opsonic) system.
    [Show full text]